T1	intervention 45 64	omega 3 fatty acids
T2	condition 83 131	aromatase inhibitor-induced musculoskeletal pain
T3	control 556 563	placebo
T4	duration 568 576	24Â weeks
T5	eligibility 580 639	postmenopausal breast cancer patients starting adjuvant AIs
T6	outcome-Measure 664 690	adherence and tolerability
T7	outcome-Measure 720 755	inflammatory cytokines and symptoms
T8	No-of-participants 912 922	Forty-four
T9	No-of-participants 955 957	35
T10	outcome 979 988	Adherence
T11	outcome 1125 1143	grade 1 flatulence
T12	intervention-value 1145 1148	55%
T14	outcome 1169 1177	belching
T15	intervention-value 1179 1182	45%
T16	outcome 1200 1234	Mean pain severity scores (BPI-SF)
T17	outcome 1290 1330	Quality of life, based on FACT-ES scores
T18	outcome 1533 1549	RBC n - 3 levels
